Expression of cortactin and survivin in renal cell carcinoma associated with tumor aggressiveness

World Journal of Urology

Volumn 27, Issue 4, 2009, Pages 557-563

  Wang, Giueng Chueng ^a   Hsieh, Po Shiuan ^b   Hsu, Hsian He ^c   Sun, Guang Huan ^c   Nieh, Shin ^c   Yu, Cheng Ping ^c   Jin, Jong Shiaw ^c  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Cortactin; Granular cell differentiation; Renal cell carcinoma; Sarcomatoid differentiation; Survivin

Indexed keywords

BIRC5 PROTEIN, HUMAN; CORTACTIN; MICROTUBULE ASSOCIATED PROTEIN; TUMOR MARKER;

ARTICLE; CANCER STAGING; DISEASE COURSE; HOSPITALIZATION; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; METABOLISM; MICROARRAY ANALYSIS; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY;

CARCINOMA, RENAL CELL; CORTACTIN; DISEASE PROGRESSION; HUMANS; KIDNEY NEOPLASMS; MICROARRAY ANALYSIS; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TUMOR MARKERS, BIOLOGICAL;

EID: 68549133519     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-009-0376-2     Document Type: Article

References (37)

1. Aznavoorian S, Murphy AN, Stetler-Stevenson WG et al (1993) Molecular aspects of tumor cell invasion and metastasis. Cancer 71:1368-1383. doi: 10.1002/1097-0142(19930215)71:4<1368::AID-CNCR2820710432>3.0.CO;2-L
2. Bonsib SM, Gibson D, Mhoon M et al (2000) Renal sinus involvement in renal cell carcinomas. Am J Surg Pathol 24:451-458. doi: 10.1097/ 00000478-200003000-00015
3. Sweeney P, Wood CG, Pisters LL et al (2003) Surgical management of renal cell carcinoma associated with complex inferior vena caval thrombi. Urol Oncol 21:327-333. doi: 10.1016/S1078-1439(02)00280-6
4. Atkins MB, Regan M, McDermott D (2004) Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin Cancer Res 10:4346S-6342S. doi: 10.1158/ 1078-0432.CCR-040029
5. Flanigan RC (2004) Debulking nephrectomy in metastatic renal cancer. Clin Cancer Res 10:6335S-6341S. doi: 10.1158/1078-0432.CCR-sup-040026
6. Partin AW, Shoeniger JS, Mohler LL et al (1989) Fourier analysis of cell motility: Correlation of motility with metastatic potentials. Proc Natl Acad Sci USA 86:1254-1258. doi: 10.1073/pnas.86.4.1254
7. Lauffenburger DA, Horwitz AF (1996) Cell migration: A physically integrated molecular process. Cell 84:359-369. doi: 10.1016/ S0092-8674(00)81280-5
8. Rothschild BL, Shim AH, Ammer AG et al (2006) Cortactin overexpression regulates actin-related protein 2/3 complex activity, motility, and invasion in carcinomas with chromosome 11q13 amplification. Cancer Res 66:8017-8025. doi: 10.1158/0008-5472.CAN-05-4490
9. van Rossum AG, Schuuring-Scholters E, n Seggelen V et al (2005) Comparative genome analysis of cortactin and HS1: The significance of the F-actin binding repeat domain. BMC Genomics 6:15-17. doi: 10.1186/ 1471-2164-6-15
10. Daly RJ (2004) Cortactin signalling and dynamic actin networks. Biochem J 382:13-25. doi: 10.1042/BJ20040737
11. Luo ML, Shen XM, Zhang Y et al (2006) Amplification and overexpression of CTTN (EMS1) contribute to the metastasis of esophageal squamous cell carcinoma by promoting cell migration and anoikis resistance. Cancer Res 66:11690-11699. doi: 10.1158/0008-5472.CAN-06-1484
12. Fantozzi I, Grall D, Cagnol S et al (2008) Overexpression of cortactin in head and neck squamous cell carcinomas can be uncoupled from augmented EGF receptor expression. Acta Oncol 47(8):1502-1512. doi: 10.1080/02841860802089801
13. Li X, Zheng H, Hara T et al (2008) Aberrant expression of cortactin and fascin are effective markers for pathogenesis, invasion, metastasis and prognosis of gastric carcinomas. Int J Oncol 33(1):69-79
14. Lin CK, Su HY, Tsai WC et al (2008) Association of cortactin, fascin-1 and epidermal growth factor receptor (EGFR) expression in ovarian carcinomas: Correlation with clinicopathological parameters. Dis Markers 25(1):17-26
15. Gibcus JH, Mastik MF, Menkema L et al (2008) Cortactin expression predicts poor survival in laryngeal carcinoma. Br J Cancer 98(5):950-955. doi: 10.1038/sj.bjc.6604246
16. Sah NK, Khan Z, Khan GJ et al (2006) Structural, functional and therapeutic biology of survivin. Cancer Lett 244:164-171. doi: 10.1016/ j.canlet.2006.03.007
17. Ambrosini G, Adida C, Altieri DC (1997) A novel antiapoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917-921. doi: 10.1038/nm0897-917
18. Reed JC, Bischoff JR (2000) BIRinging chromosomes through cell division - and survivin the experience. Cell 102:545-548. doi: 10.1016/ S0092-8674(00)00076-3
19. Tran J, Master Z, Yu JL et al (2002) A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA 99:4349-4354. doi: 10.1073/pnas.072586399
20. Tran J, Rak J, Sheehan C et al (1999) Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem Biophys Res Commun 264:781-788. doi: 10.1006/ bbrc.1999.1589
21. Blanc-Brude OP, Mesri M, Wall NR et al (2003) Therapeutic targeting of the survivin pathway in cancer: Initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin Cancer Res 9:2683-2692
22. Ryan BM, Konecny GE, Kahlert S et al (2006) Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol 17:597-604. doi: 10.1093/annonc/mdj121
23. Hidalgo A, Pina P, Guerrero G et al (2003) A simple method for the construction of a small format tissue arrays. J Clin Pathol 56:144-146. doi: 10.1136/jcp.56.2.144
24. Jin JS, Hsieh DS, Loh SH et al (2006) Increasing expression of serine protease matriptase in ovary tumors: Tissue microarray analysis of immunostaining score with clinicopathological parameters. Mod Pathol 19:447-452. doi: 10.1038/modpathol.3800495
25. Rosenthal EL, Shreenivas S, Peters GE et al (2003) Expression of extracellular matrix metalloprotease inducer in laryngeal squamous cell carcinoma. Laryngoscope 113:1406-1410. doi: 10.1097/ 00005537-200308000-00027
26. van Rossum AG, Moolenaar WH, Schuuring E (2006) Cortactin affects cell migration by regulating intercellular adhesion and cell spreading. Exp Cell Res 312:1658-1670. doi: 10.1016/j.yexcr.2006.01.033
27. Ormandy CJ, Musgrove EA, Hui R et al (2003) Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat 78:323-335. doi: 10.1023/A:1023033708204
28. Xiang Y, Yao H, Wang S et al (2006) Prognostic value of survivin and livin in nasopharyngeal carcinoma. Laryngoscope 116:126-130. doi: 10.1097/01.mlg.0000187392.87904.35
29. Zhu H, Chen XP, Zhang WG et al (2005) Expression and significance of new inhibitor of apoptosis protein survivin in hepatocellular carcinoma. World J Gastroenterol 11:3855-3859
30. Bhanot U, Hevdrich R, Moller P et al (2006) Survivin expression in pancreatic intraepithelial neoplasia (PanIN): Steady increase along the developmental stages of pancreatic ductal adenocarcinoma. Am J Surg Pathol 30:754-759. doi: 10.1097/00000478-200606000-00013
31. Wu YK, Chen KT, Kuo YB et al (2009) Quantitative detection of survivin in malignant pleural effusion for the diagnosis and prognosis of lung cancer. Cancer Lett 273(2):331-335. doi: 10.1016/j.canlet.2008.08.023
32. Invernizzi R, Travaglino E, Benatti C et al (2006) Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia. Eur J Haematol 76:494-501. doi: 10.1111/j.0902-4441.2006.t01-1-EJH2588.x
33. Antonaci A, Consorti F, Mardente S et al (2008) Survivin and cyclin D1 are jointly expressed in thyroid papillary carcinoma and microcarcinoma. Oncol Rep 20(1):63-67
34. Grotty TB, Farrow GM, Lieber MM (1995) Chromophobe cell renal carcinoma, clinicopathological features of 50 cases. J Urol 154:964-967. doi: 10.1016/S0022-5347(01)66944-1
35. Murphy WM, Grignon DJ, Perlman EJ (2004) Chromophobe renal cell carcinoma. In: Silverberg SG and Sobin LH (eds) Atlast of tumor pathology. Tumours of the kidney, bladder, and related urinary structures, 3rd edn. AFIP, Washington, pp 130-136
36. Moch H, Gasser T, Amin MB et al (2000) Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: A Swiss experience with 588 tumors. Cancer 89:604-614. doi: 10.1002/ 1097-0142(20000801)89:3<604::AID-CNCR16>3.0.CO;2-Q
37. Lohse CM, Blute ML, Zincke H et al (2002) Comparison of standardized and nonstandardized nuclear grade of renal cell carcinoma to predict outcome among 2,042 patients. Am J Clin Pathol 118:877-886. doi: 10.1309/ VLV6-BRTR-HY5B-H485